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Background. The International Society for Peritoneal Dial-
ysis (ISPD) treatment guidelines for continuous ambulatory
peritoneal dialysis (CAPD) peritonitis 2000 recommended the
use of cefazolin plus ceftazidime as the initial empirical ther-
apy in patients with residual renal function (RRF). However,
this treatment regimen has not been compared with the con-
ventional regimen of cefazolin plus netilmicin in prospective,
randomized controlled trials.
Methods. Stable CAPD patients who developed clinical evi-
dence of peritonitis were randomized to receive intraperitoneal
(i.p.) cefazolin plus netilmicin or cefazolin plus ceftazidime once
daily in the long dwell for 14 days. For patients with RRF
(>1 mL/minute) before entry into the study (N = 50), RRF
and 24-hour urine volume were measured at days 1, 14, and 42
after commencement of i.p. antibiotic treatment.
Results. One hundred and two patients were recruited into
the study. The primary cure rates of i.p. cefazolin plus netilmicin
and cefazolin plus ceftazidime were 66.7% and 64.7%, respec-
tively. The overall cure rate for the 2 treatment regimens was
82.3% for both. Seven patients (14%) from each treatment
group required removal of the dialysis catheters due to treat-
ment failure. Relapse of peritonitis occurred in 2 patients (4%)
in both treatment groups. Thirty-six patients with RRF at base-
line achieved primary cure of their peritonitis by the assigned
antibiotics. In this subgroup of patients, their RRF and daily
urine volume showed significant reduction at day 14 and re-
turned to near baseline values at day 42. The degree of reduction
in RRF and urine volume did not differ significantly between
the patients treated with cefazolin plus netilmicin and cefazolin
plus ceftazidime.
Conclusion. Intraperitoneal cefazolin plus netilmicin and
cefazolin plus ceftazidime have similar efficacy as empirical
treatment for CAPD peritonitis. In CAPD patients with RRF,
significant but reversible reduction in RRF and 24-hour urine
volume could occur after an episode of peritonitis, despite suc-
cessful treatment by i.p. antibiotics. The effect of i.p. cefazolin
plus netilmicin, or i.p. cefazolin plus ceftazidime on RRF in
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CAPD patients with peritonitis does not appear to be different.
Our findings do not support the routine use of cefazolin and
ceftazidime as the empirical treatment for CAPD peritonitis.
In recent years, it has been recognized that preserva-
tion of residual renal function (RRF) in patients undergo-
ing continuous ambulatory peritoneal dialysis (CAPD) is
associated with improved survival and better quality of
life [1, 2]. The factors that influence the rate of loss of
RRF in CAPD patients have not been completely elu-
cidated. It has been suggested that higher rate of peri-
tonitis, the presence of diabetes mellitus, and obesity are
associated with a more rapid loss of RRF [3–5]. It has
also been reported that CAPD patients who have been
treated with aminoglycosides have a faster rate of de-
cline of RRF [4, 6]. In view of the potential nephrotoxic
effect of aminoglycosides, the International Society for
Peritoneal Dialysis (ISPD) guidelines for the treatment
of CAPD peritonitis 2000 recommended that a first and
a third generation cephalosporin, such as cefazolin plus
ceftazidime, be used as the initial empirical antibiotic
treatment for CAPD-related peritonitis, and that the con-
ventional regimen of cefazolin plus netilmicin be avoided
in patients with RRF [7].
However, it should be noted that the clinical efficacy
of cefazolin plus ceftazidime for the treatment of CAPD
peritonitis has not been compared with cefazolin plus
netilmicin in prospective randomized clinical trials. There
is also a lack of prospective data regarding the effect of a
single episode of peritonitis and the use of intraperitoneal
(i.p.) aminoglycosides on RRF in CAPD patients.
The aim of this study was to compare i.p. cefazolin plus
netilmicin versus i.p. cefazolin plus ceftazidime for the
treatment of CAPD peritonitis in terms of their clinical
efficacy and their effect on RRF.
METHODS
Study design
This study was a prospective, randomized, open-
labeled study in stable CAPD patients in a single dialysis
2375
2376 Lui et al: Effect of cefazolin + netilmicin or ceftazidime on residual renal function
center of a university teaching hospital. The randomiza-
tion was done by computer generated randomization ta-
ble. The study protocol was approved by the Hospital
Ethical Committee for Clinical Research.
Subjects
All stable CAPD patients aged 18 or older in the
dialysis center who had developed clinical evidence of
peritonitis were eligible for the study. Peritonitis was di-
agnosed when abdominal pain and cloudy peritoneal dial-
ysis fluid (PDF) occurred with or without fever, and when
peritoneal white cell count (WBC) count was >100/mm3
with >50% neutrophils. Informed consent was obtained
from each patient. The flow of patients in the study is
shown in Figure 1.
Exclusion criteria
Patients who had known hypersensitivity to
cephalosporins or aminoglycosides, suspected fun-
gal or tuberculous peritonitis and relapsing peritonitis
(i.e., an episode of peritonitis within 4 weeks after
apparent recovery and cessation of antibiotics from
a previous episode of peritonitis), and active exit site
infection were excluded from the study.
Definitions
Cure is defined as complete resolution of signs and
symptoms of peritonitis with negative PDF cultures and
no further episodes of peritonitis within 28 days following
the cessation of antibiotic treatment. Primary cure refers
to cure by the assigned i.p. antibiotics. Primary treatment
failure is defined as the presence of fever, abdominal
pain, and turbid peritoneal dialysate, and if the total peri-
toneal WBC counts is >50% of the pretreatment values
after 3 days of treatment by the assigned antibiotics. Sec-
ondary cure refers to cure after adjustment of antibiotics
or changing to second line antibiotics in patients with
primary treatment failure. Secondary treatment failure is
defined as treatment failure despite adjustment of antibi-
otics or changing to second line antibiotics for 3 to 5 days
in patients with primary treatment failure. Relapse is de-
fined as recurrence of peritonitis with the same microor-
ganism within 28 days of clearing of the initial peritonitis
episode and cessation of antibiotic therapy.
Treatment regimen
Patients who fulfilled the entry criteria were random-
ized to receive either i.p. cefazolin plus netilmicin or i.p.
cefazolin plus ceftazidime, given once daily in the long
dwell. The dosage of the i.p. antibiotics were as follows:
cefazolin (1 g per 2 L PDF); netilmicin (0.6 mg/kg body
weight per 2 L PDF); and ceftazidime (1 g per 2 L PDF).
The duration of treatment was 14 days. If the peritoni-
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Fig. 1. Flow of patients in the study.
tis failed to respond to the assigned i.p. antibiotics by
day 3 (primary treatment failure), the antibiotics would
be adjusted according to the PDF bacterial culture re-
sults or be changed to second line antibiotics (vancomycin
plus amikacin) if the PDF bacterial cultures were nega-
tive. Removal of the peritoneal dialysis catheters would
be considered in patients with primary treatment failure
whose peritonitis failed to improve after adjusting the i.p.
antibiotic regimens for 3 to 5 days (secondary treatment
failure).
Monitoring
The duration of follow-up was 42 days. Before start-
ing treatment and at days 1, 3, 5, 7, 10, 14, 28 after the
initiation of treatment, peritoneal fluid total plus differ-
ential WBC count were measured. At days 0, 3, 7, 10, 14,
and 28 after the initiation of treatment, bacterial and fun-
gal cultures of fresh peritoneal effluent were performed.
Complete blood count, liver and renal function tests were
measured before and at 14 and 42 days after the initiation
of treatment.
Measurement of RRF
For patients with RRF of greater than 1 mL/min as de-
termined at the last routine follow-up before entry into
the study, their RRF and daily urine output were deter-
mined at days 1, 14, and 42 after entry into study. Es-
timated RRF was calculated as the mean of creatinine
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Table 1. Demographic data and clinical parameters of the study
population
Cefazolin + Cefazolin +
Netilmicin Ceftazidime P value
Number of patients 51 51
Age years 63.7 ± 14.6 66.7 ± 12.2 0.17
(26–89) (30–90)
Sex male:female 1.3:1 1:1 0.55
Duration of CAPD months 44.1 ± 40.5 46.3 ± 53.3 0.79
(3–157) (1–240)
Body weight kg 59.6 ± 14.1 58.6 ± 9.6 0.62
(35–89.3) (39.6–79)
Cause of renal failure
Glomerulonephritis 16 13
Diabetic nephropathy 17 13
Hypertensive nephropathy 3 6
Polycystic kidney disease 1 3
Others/unknown 14 16
Peritoneal WBC count (/mm3) 4715 ± 5188 3254 ± 3166 0.11
on presentation (164–22100) (150–13200)
Number of patients 24 (47%) 26 (51%) NS
with RRF >1 mL/min
Number of patients who have 18 18 NS
achieved primary cure
NS, not significant.
clearance and urea clearance from a 24-hour urine col-
lection. The first urine collection was started on day 0 and
completed on day 1.
Data analysis
In order to directly compare the effect of i.p. cefazolin
plus netilmicin versus i.p. cefazolin plus ceftazidime on
RRF, a subgroup of patients whose RRF was greater than
1 mL/min and who had achieved primary cure of their
peritonitis by the assigned i.p. antibiotics were subjected
to further analysis. The effect of the 2 treatment regimens
on RRF and 24-hour urine volume at days 1, 14, and 42
after the initiation of treatment were compared.
Statistical analysis
Statistical analysis was performed using SPSS (SPSS,
Chicago, IL, USA) statistical software. Numerical data
are given as mean ± SD. Means between groups were
compared with Student t test and Mann-Whitney test
when appropriate. Percentages were compared by means
of Fisher exact test. A P value equal to or less than 0.05
is considered statistically significant.
RESULTS
One hundred and two stable CAPD patients with clin-
ical evidence of peritonitis were recruited into the study
from October 2002 to October 2004. Fifty-one patients
were randomized to receive i.p. cefazolin plus netilmicin,
while the other 51 patients were randomized to receive
i.p. cefazolin plus ceftazidime. The baseline demographic
data and clinical parameters of the 2 treatment groups
are shown in Table 1. The 2 groups of patients were com-
Table 2. Profile of bacteria isolated from the PDF of patients treated
with i.p. cefazolin plus netilmicin or cefazolin plus ceftazidime
Cefazolin + Ceftazadime +
Bacterial isolates Netilmicin Cefazolin P value
Gram-positive isolates 22 (43%) 26 (51%) 0.43
MSSA 3 2
MSCNS 3 3
MRSA 0 1
MRCNS 2 0
Streptococcus species 11 13
Diphtheroid 2 6
Bacillus 1 1
Gram-negative isolates 18 (35%) 13 (25%) 0.28
Escherichia coli 8 8
Klebsiella pneumoniae 4 2
Pseudomonas species 2 2
Acinetobacter species 2 0
Others 2 1
No growth 11 (22%) 12 (24%) 0.81
Abbreviations are: MSSA, methicillin-sensitive Streptococcus aureus; MSCNS,
methicillin-sensitive coagulase negative S. aureus; MRSA, methicillin-resistant
S. aureus; MRCNS, methicillin-resistant coagulase negative S. aureus.
parable with respect to age, sex ratio, duration of CAPD,
body weight, causes of renal failure, and peritoneal WBC
count on presentation. The profile of bacterial isolates
from the PDF of the patients in the 2 treatment groups is
summarized in Table 2.
Clinical outcome
The primary cure rate of the assigned antibiotic regi-
mens for the cefazolin plus netilmicin and the cefazolin
plus ceftazidime groups was 66.7% and 64.7%, respec-
tively (P = 0.84). The overall cure rate, after allowing
for adjustment of i.p, antibiotic regimens, of the cefa-
zolin plus netilmicin and the cefazolin plus ceftazidime
groups was 82.3% for both. Seven patients (14%) from
each of the 2 treatment groups failed to respond to the i.p.
antibiotic treatment and required removal of their peri-
toneal dialysis catheters. The interval between presenta-
tion and catheter removal in the cefazolin plus netilmicin
group and cefazolin plus ceftazidime group was 7.3 ±
1.1 days and 7.1 ± 1.1 days, respectively. Relapse of peri-
tonitis occurred in 2 patients (4%) from both treatment
groups. For peritonitis caused by Gram-positive bacte-
ria, the primary cure rate in the cefazolin plus netilmicin
and cefazolin plus ceftazidime groups was 73% and 65%,
respectively (P = 0.07), whereas for peritonitis caused
by Gram-negative bacteria, the primary cure rate in the
cefazolin plus netilmicin and cefazolin plus ceftazidime
groups was 56% and 54%, respectively (P = 0.93). The
primary cure rate for culture negative peritonitis was 73%
and 75% for the cefazolin plus netilmicin and cefazolin
plus ceftazidime groups, respectively (P = 1).
Residual renal function
Fifty patients had RRF of >1 mL/min before entry
into the study. Thirty-six out of these 50 patients achieved
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Table 3. Demographic data and clinical parameters of patients with
RRF who had achieved primary cure of their peritonitis by i.p.
cefazolin plus netilmicin or cefazolin plus ceftazidime
Netilmicin + Ceftazadime +
Cefazolin Cefazolin P value
Number of patients 18 18
Age years 64.4 ± 14.5 63.9 ± 13.0 0.92
(31–85) (32–80)
Sex male:female 2.6:1 2:1 0.62
Duration of CAPD months 20.1 ± 19.1 15.3 ± 15.4 0.38
(3–68) (3–59)
Body weight kg 64.5 ± 9.6 57.9 ± 9.4 0.09
(40–82.8) (40.5–76.7)
Renal diagnosis
Glomerulonephritis 5 4
Diabetes mellitus 5 6
Hypertension 2 2
Polycystic kidney disease 0 1
Other/unknown 6 5
Table 4. Profile of bacteria isolated from the PDF in patients with
RRF who had achieved primary cure of their peritonitis by the 2
treatment groups
Cefazolin + Cefazolin +
Netilmicin Ceftazidime
Streptococcus species 3 6
MSCNS 3 2
MSSA 1 1
Escherichia coli 3 3
Klebsiella pneumoniae 2 0
Diphtheroid 0 1
Culture negative 6 5
MSCNS, methicillin-sensitive coagulase negative S. aureus; MSSA, methicillin-
sensitive S. aureus.
primary cure of their peritonitis by the assigned antibi-
otic regimens. Eighteen patients were treated by cefazolin
plus netilmicin, while the other 18 patients were treated
by cefazolin plus ceftazidime. The baseline demographic
data and clinical parameters of the 2 treatment groups
are shown in Table 3. The 2 groups of patients were com-
parable with respect to age, sex ratio, duration of CAPD,
and causes of renal failure. The profile of bacteria causing
the peritonitis in the 2 treatment groups were also similar
(Table 4).
Figure 2 shows the change of PDF total WBC count
with time in the 2 treatment groups. The serial change in
RRF of the patients in the 2 treatment groups is shown
in Figure 3. The RRF of both treatment groups was sim-
ilar on day 1 (4.16 ± 2.54 mL/min in the cefazolin plus
netilmicin group vs. 3.90 ± 2.99 mL/min in the cefazolin
plus ceftazidime group, P = 0.65). After 14 days of i.p. an-
tibiotic treatment, there was a marked reduction of RRF
in both treatment groups. In the cefazolin plus netilmicin
group, the RRF decreased from 4.16 ± 2.54 mL/min to
2.82 ± 2.58 mL/min (P < 0.001). Similarly, the RRF of
the patients in the cefazolin plus ceftazidime group de-
creased significantly from 3.90 ± 2.99 mL/min to 2.58 ±
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2.08 mL/min (P = 0.018). The percentage change in RRF
in the cefazolin plus netilmicin and the cefazolin plus cef-
tazidime groups at day 14 were 32% and 34%, respec-
tively (P = 0.24). Four weeks later or at day 42, the RRF
of both treatment groups had returned to values close to
the baseline as at day 1 (4.25 ± 3.08 mL/min vs. 4.16 ±
2.54 mL/min P = 0.79 for the cefazolin plus netilmicin
group and 4.00 ± 2.71 mL/min vs. 3.90 ± 2.99 mL/min
P = 0.76 for the cefazolin plus ceftazidime group).
Figure 4 shows the serial change in 24-hour urine
volume of the patients in the 2 treatment groups. The
24-hour urine volume in both treatment groups at day 1
was similar (924 ± 528 mL in the cefazolin plus netilmicin
group vs. 895 ± 507 mL in the cefazolin plus ceftazidime
group, P = 0.74). After completion of i.p. antibiotic treat-
ment at day 14, the 24-hour urine volume of patients in
both treatment groups decreased significantly compared
to the baseline values. In the cefazolin plus netilmicin
group, the 24-hour urine volume dropped from 924 ±
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528 mL to 487 ± 347 mL (P < 0.001), whereas in the ce-
fazolin plus ceftazidime group, the 24-hour urine volume
dropped from 895 ± 507 mL to 587 ± 385 mL (P = 0.001).
The percentage change in the 24-hour urine volume in
the cefazolin plus netilmicin and the cefazolin plus cef-
tazidime groups were 47% and 34%, respectively (P =
0.28). By day 42 after entry into the study, the 24-hour
urine of both treatment groups had risen back to near
baseline values as at day 1 (828±510 mL vs. 924±528 mL,
P = 0.15, for the cefazolin plus netilmicin group and 799 ±
546 mL vs. 895 ± 507 mL, P = 0.39, for the cefazolin plus
ceftazidime group).
DISCUSSION
In this study, we confirmed that i.p cefazolin plus
netilmicin and cefazolin plus ceftazidime have similar ef-
ficacy as empirical treatment for CAPD peritonitis. In ad-
dition, we observed that there was a significant, although
reversible, reduction in RRF at day 14 after an episode
of peritonitis, despite prompt response of the peritonitis
to i.p. antibiotics. Lastly, we found that patients treated
with i.p. cefazolin plus netilmicin or i.p. cefazolin plus cef-
tazidime had similar degree of reduction in RRF at day
14 after peritonitis.
The findings of our study provided confirmatory evi-
dence that i.p cefazolin plus netilmicin and i.p cefazolin
plus ceftazidime are equally effective as empirical treat-
ment for CAPD peritonitis. These findings are to be ex-
pected because the antibacterial coverage of netilmicin
and ceftazidime are similar. As a matter of fact, the main
reason why the ISPD guidelines 2000 recommended the
use of i.p cefazolin plus ceftazidime instead of i.p cefa-
zolin plus netilmicin for the treatment of CAPD peri-
tonitis is that the former combination is believed to be
less nephrotoxic, not that it is more effective.
In our study, the significant reduction in RRF and
24-hour urine volume at the completion of 14 days’ i.p. an-
tibiotic treatment in patients who had achieved primary
cure of their peritonitis is noteworthy. This is because
the peritonitis in these patients had responded promptly
to the i.p. antibiotics such that their clinical signs and
symptoms of peritonitis had resolved by day 3 after the
initiation of treatment. One would therefore expect the
peritonitis to have resolved completely and not to have
any significant impact on RRF after 14 days of i.p. antibi-
otic treatment. The reason for the seemingly paradoxic
deterioration in RRF despite prompt resolution of the
peritonitis was not entirely clear. It has been reported that
in CAPD patients, there was an active release of proin-
flammatory cytokines and growth factors through at least
6 weeks after apparent clinical remission of peritonitis [8].
It has also been shown that the levels of interleukin-6 and
interleukin-8 in the PDF and plasma were significantly
increased during peritonitis in patients on CAPD [9]. In
cirrhotic patients with spontaneous bacterial peritonitis,
it has been demonstrated that the plasma and ascitic fluid
cytokine levels were significantly higher in those patients
who developed renal impairment, suggesting that the in-
flammatory response to infection might be an important
mechanism of renal impairment [10]. It is therefore plau-
sible to postulate that bacterial peritonitis in CAPD pa-
tients could trigger off a systemic inflammatory reaction,
which persists despite resolution of the clinical signs and
symptoms of peritonitis. Such systemic inflammatory re-
action, with its associated increased production of proin-
flammatory cytokines and growth factors, could adversely
affect RRF. Other factors such as change in intravascular
volume and filling pressures might also contribute to the
decrease in RRF during peritonitis.
The reduction in RRF of our patients after bacterial
peritonitis was not permanent but reversible. Both the
RRF and the 24-hour urine volume of our patients re-
turned to near baseline values at day 42 after an initial
decrease at day 14. Our observation is echoed by the study
of Dittrich et al, which showed that application of radio-
graphic contrast media in CAPD patients also led to a
significant but temporary decline in RRF [11]. In most
previous studies, it has been suggested that higher rate
of peritonitis is associated with a faster decline in RRF
in CAPD patients [3, 4]. It is possible that although the
acute effect of a single episode of bacterial peritonitis
on RRF might be reversible, the cumulative effect of re-
peated episodes of peritonitis could lead to irreversible
renal damage. It should be pointed out that the baseline
RRF in our study was actually measured on day 1 af-
ter the patients had developed peritonitis and could have
already started to decline. Nonetheless, because it was
not possible to measure the RRF immediately before the
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patient develops peritonitis, the baseline RRF measured
in our study is probably the best estimate of the genuine
baseline RRF.
Gucket at al previously reported a prospective, ran-
domized controlled trial of cefazolin plus netilmicin ver-
sus ceftazidime plus vancomycin in the treatment of
CAPD peritonitis [12]. However, to the best of our knowl-
edge, our study is the first one to compare the effect of
cefazolin plus netilmicin and cefazolin plus ceftazidime
on RRF in CAPD patients with bacterial peritonitis in
a prospective, randomized fashion. Our results did not
substantiate the notion that i.p. cefazolin plus netilmicin
is more nephrotoxic than i.p. cefazolin plus ceftazidime in
CAPD patients with RRF. In a recent study, Baker et al
also showed that there were no significant differences
in the rate of decline of RRF in CAPD patients treated
with and without gentamicin for CAPD peritonitis [13].
Although it is well established that aminoglycosides are
nephrotoxic, their nephrotoxicity is dose dependent [14,
15]. In our study, the dose of netilmicin used was rela-
tively low. In addition, we had adopted the intermittent,
once daily regimen of netilmicin administration, which
has been shown to be less nephrotoxic [16]. These factors
could have explained why in our study, i.p. cefazolin plus
netilmicin was not more nephrotoxic than i.p. cefazolin
plus ceftazidime. The routine use of a third generation
cephalosporin for the treatment of peritonitis also has
the potential disadvantage of encouraging the emergence
of vancomycin-resistant enterococci [17] and extended-
spectrum beta lactamase producing enterobacteriaceae
[18]. Taken together, we would recommend the continue
use of i.p. cefazolin plus netilmicin as the empirical treat-
ment for CAPD peritonitis.
CONCLUSION
Intraperitoneal cefazolin plus netilmicin and i.p. cefa-
zolin plus ceftazidime have similar efficacy as empirical
treatment for CAPD peritonitis. A single episode of bac-
terial peritonitis, despite successful treatment by i.p. an-
tibiotics, could result in a significant, although reversible,
reduction in RRF. The degree of reduction in RRF ap-
pears to be similar in patients treated with i.p cefazolin
plus netilmicin or i.p. cefazolin plus ceftazidime. Our find-
ings do not support the routine use of a first and a third
generation cephalosporin in the empirical treatment of
CAPD peritonitis. Further studies are warranted to elu-
cidate the underlying mechanism for the reversible reduc-
tion in RRF after bacterial peritonitis despite apparent
cure by i.p. antibiotics.
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